A Phase 3 interventional study of Nilotinib and Best Supportive Care (BSC) +/- imatinib or sunitinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 35 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 4 in phase 3, and was the 3rd registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2007.
This study's enrollment of 248 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 35 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2007, is one of 4 in phase 3, and was the 6th registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.
Inclusion criteria (Core Phase):
Inclusion criteria (Extension Phase):
Exclusion criteria (Core Phase):
Exclusion criteria (Extension Phase):
Other protocol-defined inclusion/exclusion criteria applied
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400mg twice daily in core and extension phases of the study.
Drug: Nilotinib
In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm. Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression.
Drug: Nilotinib · Other: Best Supportive Care (BSC) +/- imatinib or sunitinib
Nilotinib 400 mg twice daily (bid)
Also known as: AMN107, Tasigna®
Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)
Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.
Time frame: Up to 16 months
Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
PFS is defined as the time from the first date of cross-over to nilotinib therapy from the control arm to the date of the first observation of documented disease progression. Tumor assessment was based on the local investigator's measurement using Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.
Time frame: Up to 34 months
Overall Survival Based on Primary Analysis (Data Cut-off:June, 2008)
Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact.
Time frame: Up to 16 months
Overall Survival During Core and Extension Phases of the Study
Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact. This analysis included both Core and Extension data as well as survival follow up data.
Time frame: Up to 50 months (including core, extension and follow up period)
Overall Survival for Treatment Crossover Analysis Set
For patients who crossed-over to nilotinib from the control arm, the overall survival was the time from the first dose date of nilotinib after switching from control arm to the date of death due to any cause. If death was not observed, the OS was censored at the latest date the patient was known to be alive.
Time frame: Up to 34 months
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)
The best overall response is the best response recorded from randomization until disease progression. The CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).
Time frame: Up to 16 months
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
The best overall response (CR/PR) must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).
Time frame: Up to 34 months
Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)
The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.
Time frame: Up to 16 months
Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.
Time frame: Up to 34 months
Patients ongoing on treatment at primary analysis had option to enter extension. Patients in control arm were allowed cross over to Nilotinib arm at disease progression and considered as part of extension. Patients entering the extension part on control arm were permitted to cross over to the nilotinib only upon documented disease progression.
| Milestone | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Started | 165 | 83 |
| Crossover to nilotinib:started extension | 0 | 53 |
| Completed | 58 | 16 |
| Not completed | 107 | 67 |
| Withdrew: Adverse event | 18 | 6 |
| Withdrew: Death | 8 | 4 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Abnormal laboratory value | 1 | 0 |
| Withdrew: Disease progression | 78 | 53 |
| Withdrew: Administrative problem | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Milestone | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Started | 41 | 67 |
| Started:crossover before primaryanalysis | 0 | 53 |
| Started:crossover after primaryanalysis | 0 | 4 |
| Started:crossover during extension | 0 | 10 |
| Completed | 0 | 0 |
| Not completed | 41 | 67 |
| Withdrew: Adverse event | 3 | 12 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Death | 1 | 7 |
| Withdrew: Protocol deviation | 3 | 1 |
| Withdrew: Treatment duration as per protocol | 0 | 1 |
| Withdrew: Disease progression | 32 | 44 |
| Withdrew: New cancer therapy | 1 | 0 |
| Withdrew: Administrative problem | 1 | 0 |
Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.
| days | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008) | 109.0 (61.0 to 113.0) | 111.0 (60.0 to 116.0) |
Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact.
| days | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Overall Survival Based on Primary Analysis (Data Cut-off:June, 2008) | 332.0 (246.0 to NA) | 280.0 (240.0 to 372.0) |
Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact. This analysis included both Core and Extension data as well as survival follow up data.
| days | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Overall Survival During Core and Extension Phases of the Study | 361 (265 to 425) | 300 (246 to 386) |
For patients who crossed-over to nilotinib from the control arm, the overall survival was the time from the first dose date of nilotinib after switching from control arm to the date of death due to any cause. If death was not observed, the OS was censored at the latest date the patient was known to be alive.
| days | Control/Cross Over to Nilotinib |
|---|---|
| Overall Survival for Treatment Crossover Analysis Set | 231 (196 to 327) |
PFS is defined as the time from the first date of cross-over to nilotinib therapy from the control arm to the date of the first observation of documented disease progression. Tumor assessment was based on the local investigator's measurement using Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.
| days | Control/Cross Over to Nilotinib |
|---|---|
| Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set | 84 (56 to 109) |
The best overall response is the best response recorded from randomization until disease progression. The CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).
| Participants | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008) | 1 (0.0 to 3.3) | 0 (0.0 to 0.0) |
The best overall response (CR/PR) must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).
| Participants | Control/Cross Over to Nilotinib |
|---|---|
| Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set | 1 (0.0 to 8.0) |
The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.
| Percentage of Participants | Nilotinib | Control/Cross Over to Nilotinib |
|---|---|---|
| CR/PR/SD | 52.7 (44.8 to 60.5) | 44.6 (33.7 to 55.9) |
| CR/PR/SD lasting > 6 months | 7.3 (3.8 to 12.4) | 1.2 (0.0 to 6.5) |
| CR/PR/SD lasting > 12 months | 0.6 (0.0 to 3.3) | 0 (0 to 0) |
The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.
| Percentage of Participants | Control/Cross Over to Nilotinib |
|---|---|
| CR/PR/SD | 37.3 (25.8 to 50.0) |
| CR/PR/SD lasting > 6 months | 7.5 (2.5 to 16.6) |
| CR/PR/SD lasting > 12 months | 6.0 (1.7 to 14.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib(Core +Extension) | — | 81/165 (49.1%) | 159/165 (96.4%) |
| Control(Core + Extension) | — | 27/83 (32.5%) | 73/83 (88%) |
| Crossover Nilotinib Therapy | — | 32/67 (47.8%) | 58/67 (86.6%) |
| Event | Nilotinib(Core +Extension) | Control(Core + Extension) | Crossover Nilotinib Therapy |
|---|---|---|---|
| General physical health deteriorationGeneral disorders | 16/165 | 3/83 | 10/67 |
| Abdominal painGastrointestinal disorders | 21/165 | 5/83 | 3/67 |
| AnaemiaBlood and lymphatic system disorders | 6/165 | 7/83 | 5/67 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/165 | 1/83 | 4/67 |
| VomitingGastrointestinal disorders | 9/165 | 1/83 | 1/67 |
| Oedema peripheralGeneral disorders | 0/165 | 0/83 | 3/67 |
| PyrexiaGeneral disorders | 5/165 | 2/83 | 1/67 |
| ConstipationGastrointestinal disorders | 1/165 | 0/83 | 2/67 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/165 | 2/83 | 2/67 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/165 | 0/83 | 2/67 |
| Event | Nilotinib(Core +Extension) | Control(Core + Extension) | Crossover Nilotinib Therapy |
|---|---|---|---|
| NauseaGastrointestinal disorders | 51/165 | 33/83 | 13/67 |
| Abdominal painGastrointestinal disorders | 61/165 | 19/83 | 13/67 |
| Oedema peripheralGeneral disorders | 30/165 | 26/83 | 13/67 |
| VomitingGastrointestinal disorders | 33/165 | 25/83 | 14/67 |
| Weight decreasedInvestigations | 34/165 | 7/83 | 20/67 |
| Decreased appetiteMetabolism and nutrition disorders | 47/165 | 18/83 | 16/67 |
| AstheniaGeneral disorders | 46/165 | 6/83 | 9/67 |
| FatigueGeneral disorders | 46/165 | 15/83 | 12/67 |
| ConstipationGastrointestinal disorders | 41/165 | 9/83 | 10/67 |
| DiarrhoeaGastrointestinal disorders | 28/165 | 20/83 | 5/67 |
| Age, Categorical(Participants) | Nilotinib | Control/Cross Over to Nilotinib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 118 | 57 | 175 |
| >=65 years | 47 | 26 | 73 |
| Age Continuous(years) | Nilotinib | Control/Cross Over to Nilotinib | Total |
|---|---|---|---|
| Mean | 57.4 ± 12.69 | 58.6 ± 10.57 | 57.8 ± 12.01 |
| Sex: Female, Male(Participants) | Nilotinib | Control/Cross Over to Nilotinib | Total |
|---|---|---|---|
| Female | 64 | 36 | 100 |
| Male | 101 | 47 | 148 |
| Race (NIH/OMB)(Participants) | Nilotinib | Control/Cross Over to Nilotinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 11 | 32 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 2 | 4 | 6 |
| White | 134 | 67 | 201 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 1 | 7 |
The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Gastrointestinal Stromal Tumors →